How about the brand Kang Yuan Pharmaceuticals?

Jiangsu Kang Yuan Pharmaceutical Co., Ltd. is a large-scale traditional Chinese medicine enterprise integrating research and development, production and sales of centralized medicines, a national key high-tech enterprise, a national technological innovation demonstration enterprise, one of the top 100 enterprises in China's pharmaceutical industry (29th), one of the top 10 traditional Chinese medicine enterprises in the country, and one of the top 20 Chinese pharmaceutical enterprises in terms of innovativeness, with a total of more than 5,000 employees. With more than 5,000 employees, the company has set up several national research platforms such as the State Key Laboratory of New Technology of Traditional Chinese Medicine Pharmaceutical Process, which was honored as the "State Key Laboratory of Excellent Enterprises" (the first one in the field of pharmaceuticals) in 2018. It has obtained 47 national new drugs of traditional Chinese medicines and 331 invention patents; undertaken more than 50 scientific and technological projects; won one second prize for national technological invention, two second prizes for national scientific and technological progress, and eight first prizes for provincial and ministerial scientific and technological progress (including two first prizes for scientific and technological progress in Jiangsu Province); and ranked the first place in the list of "Traditional Chinese Medicine R & D Power Ranking" for three consecutive years in terms of its R & D strength. The R&D strength has been ranked first in the "Chinese Medicine R&D Strength Ranking" for three consecutive years. Guizhi Poria capsule has completed the U.S. phase II clinical trials, is the internationalization of China's traditional Chinese medicine demonstration varieties.